🏅 FDA Orphan Designation
ALIQOPA
copanlisib
Manufacturer: Bayer US LLC
Indicated for:
Follicular lymphomaOrphan
FDA-Approved Indications (1)
Follicular lymphomaOrphan Designation
Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Indications & Usage
Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
💙 Support Programs
View all →ALIQOPA
Bayer US LLC
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.